Valuation: BriaCell Therapeutics Corp.

Market Cap 29.89M 25.9M 24.48M 22.23M 41.66M 2.87B 41.91M 292M 113M 1.45B 112M 110M 4.64B P/E 2024
-2.56x
P/E 2025 -0.12x
Enterprise Value 12.02M 10.42M 9.85M 8.94M 16.76M 1.15B 16.86M 118M 45.43M 585M 45.17M 44.17M 1.86B EV / Sales 2024
-
EV / Sales 2025 -
Free-Float
99.49%
Yield 2024 *
-
Yield 2025 -
Sep. 11 Neonc Technologies Holdings, Briacell Therapeutics and Oncolytics Biotech Have Report Clinical and Regulatory Developments Across Brain, Breast and Colorectal Cancer CI
Sep. 08 BriaCell Therapeutics Corp. Expands Pivotal Phase 3 Metastatic Breast Cancer Study To Memorial Sloan Kettering Cancer Center CI
Sep. 01 Certain Common Shares of BriaCell Therapeutics Corp. are subject to a Lock-Up Agreement Ending on 2-SEP-2026. CI
Sep. 01 Certain Warrants of BriaCell Therapeutics Corp. are subject to a Lock-Up Agreement Ending on 2-SEP-2026. CI
Sep. 01 Certain Options of BriaCell Therapeutics Corp. are subject to a Lock-Up Agreement Ending on 2-SEP-2026. CI
Sep. 01 Certain Restricted Share Units of BriaCell Therapeutics Corp. are subject to a Lock-Up Agreement Ending on 2-SEP-2026. CI
Sep. 01 Certain Performance Share Units of BriaCell Therapeutics Corp. are subject to a Lock-Up Agreement Ending on 2-SEP-2026. CI
Aug. 24 BriaCell Therapeutics Corp. Advances Personalized Melanoma Immunotherapy Vaccine Candidate Bria-MEL+ CI
Aug. 05 BriaCell Gets FDA Approval to Start Phase 1/2a of Prostate Cancer Immunotherapy Study MT
Aug. 05 Briacell Therapeutics Corp Receives Fda Clearance to Initiate Bria-Pros+ Clinical Study in Prostate Cancer CI
Jul. 16 BriaCell Opens First Canadian Site For Phase 3 Metastatic Breast Cancer Study MT
Jul. 16 BriaCell Therapeutics Corp. Opens First Canadian Site For Pivotal Phase 3 Trial In Metastatic Breast Cancer CI
Jul. 07 BriaCell Engages Consulting and Branding Firms to Support Potential Commercialization of Bria-IMT MT
1 day+1.22%
1 week-1.39%
Current month+0.20%
1 month+5.29%
3 months+25.13%
6 months-16.30%
Current year-49.18%
1 week 4.85
Extreme 4.85
5.17
1 month 4.72
Extreme 4.72
5.75
Current year 3.68
Extreme 3.68
16.5
1 year 3.68
Extreme 3.68
20.4
3 years 3.68
Extreme 3.68
1,297.5
5 years 3.68
Extreme 3.68
2,362.5
10 years 3.68
Extreme 3.68
11,250.11
Manager TitleAgeSince
Chief Executive Officer 70 2016-10-31
Director of Finance/CFO 54 2016-01-31
Chief Tech/Sci/R&D Officer 65 2022-02-15
Director TitleAgeSince
Director/Board Member 70 2016-10-31
Chairman 41 2019-04-23
Director/Board Member 74 2019-03-06
Date Insider Type Main position Quantity % Market Cap. Importance
7/7/26 Tax

Director

45,000 0.5173%
7/7/26 Tax

Director

15,000 0.1724%
7/7/26 Option

Chief Financial Officer

28,257 0.3248%
Change 5-day change 1-year change 3-year change Capi.($)
+1.22%-1.39%-55.73%-99.60% 31.09M
+0.66%+1.83%+47.32%+97.63% 69.69B
+1.18%+0.33%+36.89%+75.87% 61.24B
+2.22%-4.83%-15.32%+360.65% 26.77B
+0.32%+5.47%+27.74%+14.91% 26.12B
-0.89%-2.34%-3.46%-15.24% 24.07B
+0.45%+6.77%+25.72%-14.56% 20.39B
0.00%-10.41%+171.96%+298.75% 15.72B
-0.21%-2.66%+45.07%+160.34% 14.07B
+0.17%-2.74%-9.79%+455.90% 14.03B
Average +0.51%-1.82%+27.04%+133.47% 27.21B
Weighted average by Cap. +0.64%-0.95%+34.95%+125.59%

Financials

2024 2025
Net sales - -
Net income -4.79M -4.15M -3.92M -3.56M -6.68M -460M -6.72M -46.85M -18.1M -233M -18M -17.6M -743M -26.31M -22.8M -21.55M -19.57M -36.67M -2.52B -36.89M -257M -99.42M -1.28B -98.84M -96.65M -4.08B
Net Debt -862K -747K -706K -641K -1.2M -82.7M -1.21M -8.43M -3.26M -41.95M -3.24M -3.17M -134M -17.87M -15.48M -14.63M -13.29M -24.9M -1.71B -25.05M -175M -67.51M -869M -67.11M -65.62M -2.77B
Logo BriaCell Therapeutics Corp.
BriaCell Therapeutics Corp. is a clinical-stage biotechnology company that develops novel immunotherapies to transform cancer care. Bria-IMT, its Phase 3 lead candidate, is a patented, off-the-shelf, cell-based, targeted immunotherapy that activates the patient’s immune system to specifically kill cancer cells without harming other cells. The Company is advancing its Bria-IMT targeted immunotherapy in combination with an immune check point inhibitor (Retifanlimab) in a pivotal Phase 3 study in metastatic breast cancer. It is also developing personalized off-the-shelf immunotherapies, Bria-OTS and Bria-OTS+, which provides a platform technology to develop personalized off-the-shelf immunotherapies for numerous types of cancer, and a soluble CD80 protein therapeutic which act both as a stimulator of the immune system, as well as an immune checkpoint inhibitor. Its pipeline also includes Bria-IMT + CPI, Bria-BRES/BRES+, Bria-PROS+, Bria-LUNG+ and Bria-MEL+.
Employees
16
Date Price Change Volume
26-09-16 CA$4.980 +1.22% 2,304
26-09-15 CA$4.920 -1.20% 6,233
26-09-14 CA$4.980 -1.19% 13,202
26-09-11 CA$5.040 +1.00% 2,962
26-09-10 CA$4.990 -1.19% 2,000

Quarterly revenue - Rate of surprise

LAST HOURS | 40% Discount: The Best Subscriber-Only Tools to Unlock Hidden Opportunities!
d
:
:
SEIZE THE OFFER!